Why does influenza evolve so rapidly and drastically?

BIOL 4141
Dr. Keever
Paula Arango
T00688137
July 5, 2024

Background Information and Introduction

Influenza is a highly mutable virus that poses a significant challenge to public health due to its rapid evolution, often rendering vaccines less effective over time. This research proposal builds on existing literature to investigate the genetic and antigenic evolution of influenza viruses and explore innovative strategies for improving vaccine design and efficacy.

Smith (2004) provides a foundational understanding of the antigenic drift of influenza, detailing the evolution of viral strains over time and their impact on immunity and vaccine efficacy. Antigenic drift refers to the gradual accumulation of mutations in the virus's surface proteins, particularly hemagglutinin and neuraminidase, which are key targets for the immune system. These mutations alter the virus's antigenic properties, enabling it to evade the host's immune response. Smith's study meticulously maps these changes, illustrating how historical influenza strains have mutated and the consequences of these mutations on the effectiveness of existing vaccines. This research highlights that because the influenza virus can change so quickly, vaccines must be updated regularly to match the currently circulating strains. This ongoing adaptation is essential to maintain vaccine efficacy and ensure that the population remains protected against new variants of the virus.

Similarly, Hensley (2014) discusses the complexities of selecting appropriate vaccine strains due to the diverse immune histories within human populations, which influence immune responses to new strains. People are exposed to different influenza strains throughout their lives, leading to a wide range of immune responses based on their individual exposure histories. This diversity means that a vaccine that works well for one group might not be as effective for another. Hensley's study underscores the challenge of designing vaccines that can provide broad protection despite these varied immune backgrounds. The interplay between pre-existing immunity and new influenza strains makes it difficult to predict which strains will be most effective in a vaccine, further complicating the process of creating universally effective vaccines.

Genomic data is crucial for studying influenza in depth. It refers to the complete set of genetic material (DNA or RNA) of an organism, in this case, influenza viruses. It includes information about the virus's genetic code, mutations, and how it evolves over time. Antigenic data, on the other hand, pertains to the specific characteristics of viral proteins (antigens) that interact with the immune system, such as hemagglutinin and neuraminidase in influenza viruses. These antigens determine how the virus is recognized and attacked by the immune system.

The integration of genomic and antigenic data is important for predicting the antigenic evolution of influenza viruses. By analyzing genomic data, researchers can track genetic mutations in the virus, which may lead to changes in viral antigens. Antigenic data allows researchers to understand how these genetic changes translate into variations in the virus's ability to evade immune responses or how it interacts with antibodies produced by vaccines or previous infections.

Neher et al. (2016) propose computational models that utilize both genomic and antigenic data. These models aim to enhance the accuracy of selecting vaccine strains by predicting how the virus's antigens might change over time based on genetic mutations. This approach improves our ability to anticipate which strains are most likely to circulate in future flu seasons, thereby optimizing vaccine effectiveness. Petrova and Russell (2017) provide a comprehensive review that emphasizes the importance of genetic and antigenic dynamics in seasonal influenza viruses. Understanding these dynamics is key for developing vaccines that effectively target circulating strains.

Taubenberger and Kash (2010) explore the evolutionary pathways and host adaptation of influenza viruses, particularly examining historical pandemics and the genetic alterations that enabled them. Their research illuminates critical mechanisms through which influenza viruses undergo genetic changes, such as reassortment and mutation, allowing them to effectively adapt to new host species. Reassortment, where different influenza virus strains exchange genetic material, can lead to the emergence of novel strains capable of infecting humans and causing pandemics. Similarly, mutations in viral genes can alter antigenic properties and enhance viral fitness in new hosts.

Cobey and Pascual (2011) introduce a theoretical framework that examines the dynamics of influenza strains in the context of host immune factors, particularly focusing on heterogeneity and immunodominance. Heterogeneity refers to the diversity among influenza strains, which arises from genetic variations that affect viral antigenicity and fitness. Immunodominance, on the other hand, pertains to the phenomenon where certain viral antigens provoke a stronger immune response compared to others, influencing the selection pressures on circulating strains. Their study highlights the competitive interactions among influenza viruses within a host population, affecting viral diversity and evolutionary trajectories.

Nelson and Holmes (2007) complement this understanding by exploring the genetic mechanisms that underpin the rapid evolution of epidemic influenza viruses. They elucidate the concepts of antigenic drift, where gradual genetic mutations in viral genes lead to minor antigenic changes, and antigenic shift, where reassortment of viral segments results in major antigenic changes. This comprehensive review integrates genetic insights with epidemiological perspectives, emphasizing the dynamic nature of influenza virus evolution and the challenges it poses for vaccine development.

The primary objective of this research proposal is to investigate the genetic and antigenic evolution of influenza viruses and to explore innovative strategies for improving vaccine design and efficacy. The specific aims are to analyze the patterns of antigenic drift and shift in influenza viruses using historical and contemporary data found in literature. In a laboratory setting, evaluate the genetic and antigenic diversity of influenza viruses in different populations. Lastly, Investigate the immune response elicited by different influenza vaccines using laboratory techniques.

This study will delve into the following hypothesis: Incorporating conserved antigenic regions into influenza vaccines will result in broader and more durable protection against diverse influenza strains.

Methods and Experimental Design

1. Virus Collection and Isolation: The study will begin by collecting influenza virus samples from various geographical regions. Samples will be obtained from public health laboratories and surveillance programs. Approximately 50 samples will be collected, ensuring distribution across different flu seasons and regions.

The collected viruses will be isolated and propagated using Madin-Darby Canine Kidney (MDCK) cell culture.

- **MDCK Cell Culture**: MDCK cells are widely used in influenza research because they are highly permissive to influenza virus infection and replication (Youil et al., 2004). The cells provide a controlled environment that facilitates the study of viral behavior and the production of viruses for vaccine development.

Each virus isolate will be confirmed using hemagglutination (HA) assays and reverse transcription-polymerase chain reaction (RT-PCR) to verify the presence of influenza RNA.

- **Hemagglutination (HA) Assay**: This assay measures the ability of influenza viruses to agglutinate red blood cells, which is indicative of the presence of viral particles. It is a quick and reliable method for detecting and quantifying influenza viruses (Hirst, 1942).
- **Reverse Transcription-Polymerase Chain Reaction (RT-PCR)**: RT-PCR is used to detect and amplify specific RNA sequences of the influenza virus. Allowing for the confirmation of influenza RNA in the samples (Mackay et al., 2002).

2. Genomic Analysis: Viral RNA will be extracted from the isolated virus samples using a standard RNA extraction kit. RT-PCR will be performed to amplify the hemagglutinin (HA) and neuraminidase (NA) genes. The amplified genes will be sequenced using Sanger sequencing or next-generation sequencing (NGS) platforms.

- **Sanger Sequencing**: Sanger sequencing is a traditional method for DNA sequencing that uses chain-terminating inhibitors to generate a series of DNA fragments of varying lengths. This method is highly accurate and is often used for sequencing individual genes or small genomic regions (Sanger et al., 1977).
- **Next-Generation Sequencing (NGS)**: NGS platforms allow for the high throughput sequencing of entire genomes. This technology can sequence millions of DNA fragments simultaneously, making it suitable for comprehensive analysis of viral genomes. NGS

provides detailed information on genetic variations, facilitating the study of viral evolution and diversity (Metzker, 2009).

3. Antigenic Characterization: Recombinant HA and NA proteins from selected virus strains will be produced using an expression system. Monoclonal antibodies and sera from vaccinated individuals will be used to assess the antigenic similarity between the recombinant proteins and circulating virus strains.

- **Monoclonal Antibodies**: These are antibodies that are derived from a single clone of cells and are therefore identical in structure and antigen specificity. Monoclonal antibodies are used because they provide a consistent and precise tool for identifying specific antigenic sites on the HA and NA proteins. They help in determining the exact changes in the antigenic properties of the virus due to mutations (Kohler & Milstein, 1975).
- **Sera from Vaccinated Individuals**: Sera contain antibodies that are produced in response to vaccination. Using sera from vaccinated individuals allows researchers to assess how well the immune response generated by the vaccine recognizes the recombinant proteins. This helps in evaluating the efficacy of current vaccines and identifying potential gaps in protection (Plotkin, 2010).

The antigenic profiles of different virus strains will be compared to identify conserved regions. These conserved regions will be potential targets for universal vaccine design.

4. Vaccine Evaluation: Experimental vaccines incorporating the identified conserved antigenic regions will be formulated. Approximately 100 mice will be divided into control and experimental groups. The experimental groups will be immunized with the formulated vaccines through injection. The control groups will receive placebo injections.

The immune response in the mice will be monitored by measuring antibody titers using enzyme-linked immunosorbent assay (ELISA) and neutralization assays at regular intervals over six months.

- **Enzyme-Linked Immunosorbent Assay (ELISA)**: ELISA is a widely used technique for measuring the concentration of antibodies in blood samples. It works by attaching antigens to a surface, then introducing a blood sample. If antibodies specific to the antigen are present, they will bind to the antigen. A secondary antibody with an enzyme attached is then added, which binds to the primary antibody. When a substrate is added, the enzyme catalyzes a reaction that produces a detectable signal, usually a color change, indicating the presence and quantity of antibodies (Engvall & Perlmann, 1971).

After the immunization period, the mice will be challenged with different influenza virus strains to assess the breadth and durability of the protection conferred by the vaccines.

Timeline:

- Virus collection and isolation: 3 months
- Genomic analysis: 4 months
- Antigenic characterization: 3 months
- Vaccine formulation and evaluation: 6 months

Research Significance

This research will significantly advance our understanding of the genetic and antigenic evolution of influenza viruses, providing critical insights for vaccine development. By identifying conserved antigenic regions and incorporating them into new vaccine formulations, the study aims to overcome the limitations of current seasonal vaccines, which often fail to provide broad and long lasting protection due to antigenic drift and shift. This approach could lead to the development of universal influenza vaccines, reducing the global burden of influenza outbreaks and pandemics. Furthermore, the integration of genomic and antigenic data will enhance our predictive capabilities, informing public health strategies and improving vaccine efficacy.

Literature Cited

Cobey, S., & Pascual, M. (2011). Consequences of host heterogeneity, epitope immunodominance, and immune breadth for strain competition. *Journal of Theoretical Biology, 270*(1), 80–87. https://doi.org/10.1016/j.jtbi.2010.11.009

Engvall, E., & Perlmann, P. (1971). Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. *Immunochemistry*, *8*(9), 871–874. https://doi.org/10.1016/0019-2791(71)90454-x

Hensley, S. E. (2014). Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. *Current Opinion in Virology, 8*, 85–89. https://doi.org/10.1016/j.coviro.2014.07.007

Hirst, G. K. (1942). THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION. The Journal of Experimental Medicine, 75(1), 49–64. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2135212/

KÖHLER, G., & MILSTEIN, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497. https://doi.org/10.1038/256495a0

Kumar, A., Meldgaard, T. S., & Bertholet, S. (2018). Novel Platforms for the Development of a Universal Influenza Vaccine. *Frontiers in Immunology, 9*. https://doi.org/10.3389/fimmu.2018.00600

Mackay, I. M. (2002). Real-time PCR in virology. Nucleic Acids Research, 30(6), 1292–1305. https://doi.org/10.1093/nar/30.6.1292

Metzker, M. L. (2009). Sequencing technologies — the next generation. Nature Reviews Genetics, 11(1), 31–46. https://doi.org/10.1038/nrg2626

Nelson, M. I., & Holmes, E. C. (2007). The evolution of epidemic influenza. *Nature Reviews Genetics, 8*(3), 196–205. https://doi.org/10.1038/nrg2053

Neher, R. A., Bedford, T., Daniels, R. S., Russell, C. A., & Shraiman, B. I. (2016). Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. *Proceedings of the National Academy of Sciences, 113*(12), E1701–E1709. https://doi.org/10.1073/pnas.1525578113

Petrova, V. N., & Russell, C. A. (2017). The evolution of seasonal influenza viruses. *Nature Reviews Microbiology, 16*(1), 47–60. https://doi.org/10.1038/nrmicro.2017.118

Plotkin, S. A. (2010). Correlates of Protection Induced by Vaccination. *Clinical and Vaccine Immunology*, *17*(7), 1055–1065. https://doi.org/10.1128/cvi.00131-10

Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences, 74(12), 5463–5467. https://doi.org/10.1073/pnas.74.12.5463

Smith, D. J. (2004). Mapping the Antigenic and Genetic Evolution of Influenza Virus. *Science, 305*(5682), 371–376. https://doi.org/10.1126/science.1097211

Taubenberger, J. K., & Kash, J. C. (2010). Influenza Virus Evolution, Host Adaptation, and Pandemic Formation. *Cell Host & Microbe, 7*(6), 440–451. https://doi.org/10.1016/j.chom.2010.05.009

Youil, R., Su, Q., Toner, T. J., Szymkowiak, C., Kwan, W-S., Rubin, B., Petrukhin, L., Kiseleva, I., Shaw, A. R., & DiStefano, D. (2004). Comparative study of influenza virus replication in Vero and MDCK cell lines. *Journal of Virological Methods*, *120*(1), 23–31. https://doi.org/10.1016/j.jviromet.2004.03.011